Skip to content

Real world study on stable coronary heart disease treated by Danshen Chuanxiong and Danshen Sanqi prescription based on retrospective cohort

Real world study on stable coronary heart disease treated by Danshen Chuanxiong and Danshen Sanqi prescription based on retrospective cohort

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000478
Enrollment
Unknown
Registered
2025-03-06
Start date
2024-07-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Exposed group:Application of Danshen Chuanxiong, Danshen sanqi formula
Control group:Danshen Chuanxiong, Danshen Sanqi formula should not be used

Sponsors

Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Consistent with the diagnostic criteria for stable coronary heart disease. (2) over 18 years of age.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patients who have received clinical trials of other new drugs within the last 3 months; (3) a combination of psychiatric alcoholic and/or psychoactive substance abusers and dependent persons; (4) Type 1 diabetes or type 2 diabetes with poor blood glucose control (fasting blood glucose >11mmol/L) or complications (kidney disease peripheral neuropathy); (5) Gastrointestinal diseases or gastrointestinal surgery may affect drug absorption and other serious diseases of the digestive system; (6) Concurrent with the following organ damage or disease: renal insufficiency (blood creatinine greater than the upper limit of normal); Abnormal liver function (ALT and AST greater than 1.5 times the upper limit of normal); Active recurrent digestive ulcers or other bleeding risk diseases; Combined with malignant tumors hematological diseases or other serious or progressive diseases of the system.

Design outcomes

Primary

MeasureTime frame
Recurrent myocardial infarction;Revascularization;Cerebral apoplexy;Cardiovascular death;

Secondary

MeasureTime frame
ICU transfer rate;Readmission time;Left ventricular systolic and diastolic function;

Countries

China

Contacts

Public ContactYunlun Li

Shandong University of Chinese Medicine

1537073722@qq.com13064012093

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026